{"id":"bis-choline-tetrathiomolybdate","safety":{"commonSideEffects":[{"rate":"null","effect":"Hemolysis"}]},"_chembl":{"chemblId":"CHEMBL4594259","moleculeType":"Small molecule","molecularWeight":"432.55"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism is thought to be beneficial in treating conditions such as Wilson's disease, where excessive copper accumulation in the brain leads to neurodegeneration. By reducing copper levels, Bis-Choline Tetrathiomolybdate may help slow or halt disease progression.","oneSentence":"Bis-Choline Tetrathiomolybdate is a chelating agent that binds to copper, reducing its availability for incorporation into ceruloplasmin and subsequent deposition in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:58:16.025Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wilson's disease"}]},"trialDetails":[{"nctId":"NCT04422431","phase":"PHASE2","title":"Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-02","conditions":"Wilson Disease","enrollment":31},{"nctId":"NCT03403205","phase":"PHASE3","title":"Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-02-22","conditions":"Wilson Disease","enrollment":214},{"nctId":"NCT04610580","phase":"PHASE1","title":"Bioavailability Study of 2 Oral Formulations of ALXN1840","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-01-31","conditions":"Healthy","enrollment":48},{"nctId":"NCT04526210","phase":"PHASE1","title":"Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-10-21","conditions":"Wilson Disease","enrollment":54},{"nctId":"NCT04526197","phase":"PHASE1","title":"Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-07-07","conditions":"Wilson Disease","enrollment":36},{"nctId":"NCT04560816","phase":"PHASE1","title":"A Study of the Cardiac Effects of ALXN1840 in Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-07-24","conditions":"Healthy","enrollment":57},{"nctId":"NCT05303324","phase":"PHASE1","title":"Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-07-04","conditions":"Healthy","enrollment":48},{"nctId":"NCT05319912","phase":"PHASE1","title":"A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2014-04-07","conditions":"Healthy","enrollment":18},{"nctId":"NCT05319899","phase":"PHASE1","title":"A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2014-01-20","conditions":"Healthy","enrollment":18},{"nctId":"NCT05686564","phase":"","title":"Early Access Program for ALXN1840 in Patients With Wilson Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"","conditions":"Wilson Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ALXN1840"],"phase":"phase_2","status":"active","brandName":"Bis-Choline Tetrathiomolybdate","genericName":"Bis-Choline Tetrathiomolybdate","companyName":"Alexion Pharmaceuticals, Inc.","companyId":"alexion-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bis-Choline Tetrathiomolybdate is a chelating agent that binds to copper, reducing its availability for incorporation into ceruloplasmin and subsequent deposition in the brain. Used for Wilson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}